AI foundation models and physics for small molecule drug discovery
Genesis Molecular AI builds generative and predictive molecular models through its GEMS platform, pairing PyTorch, Triton, CUDA and XLA with physics tools like OpenMM and GROMACS. A multi-cloud AWS and GCP footprint run on Kubernetes, Ray and Terraform points to heavy GPU training workloads. Hiring is accelerating and senior-weighted, with CMC, formulation and process chemistry projects signaling a push from discovery toward clinical-stage development.
Genesis Molecular AI is a privately held biotech company headquartered in Burlingame, California, with a laboratory in San Diego and offices in New York. It develops AI foundation models for small molecule drug design through GEMS, a platform that combines machine learning with physics-based modeling, including the Pearl structure prediction model. The company runs an internal pipeline of drug programs, including against hard-to-drug targets, and partners with pharmaceutical companies on platform collaborations. It employs 51–200 people and hires in the United States.
Its stack includes Python, PyTorch, PyTorch Lightning, PyTorch Geometric, RDKit, scikit-learn, Triton, CUDA and XLA, plus OpenMM, GROMACS and PyMOL, running on AWS and GCP with Kubernetes, Ray and Terraform.
Genesis Molecular AI is headquartered in Burlingame, California, with a laboratory in San Diego and offices in New York.
Current work includes productionizing the Pearl structure prediction model, scaling generative foundation models, building the internal Nucleus platform, and a global CMC strategy for its small molecule pipeline.
Other companies in the same industry, closest in size
Genesis Molecular AI's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.